Online inquiry

IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12597MR)

This product GTTS-WQ12597MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromboembolic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000128.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2160
UniProt ID P03951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12597MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15814MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ1621MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ2937MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ12285MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3450MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ14304MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ10168MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13722MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW